# Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT03118765** · PHASE2 · COMPLETED · sponsor: **Glenmark Specialty S.A.** · enrollment: 155 (actual)

## Conditions studied

- Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** GSP304 (tiotropium bromide) Inhalation Solution
- **DRUG:** GSP304 Placebo Inhalation Solution
- **DRUG:** Spiriva® Respimat® inhalation spray

## Key facts

- **NCT ID:** NCT03118765
- **Lead sponsor:** Glenmark Specialty S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-24
- **Primary completion:** 2017-07-31
- **Final completion:** 2017-07-31
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2019-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03118765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03118765, "Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03118765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*